BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36502288)

  • 1. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review.
    Llewellyn DC; Logan Ellis H; Aylwin SJB; Oštarijaš E; Green S; Sheridan W; Chew NWS; le Roux CW; Miras AD; Patel AG; Vincent RP; Dimitriadis GK
    Obesity (Silver Spring); 2023 Jan; 31(1):20-30. PubMed ID: 36502288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia.
    Lobato CB; Pereira SS; Guimarães M; Hartmann B; Wewer Albrechtsen NJ; Hilsted L; Holst JJ; Nora M; Monteiro MP
    Front Endocrinol (Lausanne); 2020; 11():608248. PubMed ID: 33424773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition and management of hyperinsulinemic hypoglycemia after bariatric surgery.
    Malik S; Mitchell JE; Steffen K; Engel S; Wiisanen R; Garcia L; Malik SA
    Obes Res Clin Pract; 2016; 10(1):1-14. PubMed ID: 26522879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
    Lu JM
    Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
    Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
    Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review.
    Alsayed Hasan M; Schwartz S; McKenna V; Ing R
    Obes Surg; 2023 Sep; 33(9):2927-2937. PubMed ID: 37530920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence and risk factors associated with developing symptoms of hypoglycemia after bariatric surgery.
    Lee CJ; Brown TT; Schweitzer M; Magnuson T; Clark JM
    Surg Obes Relat Dis; 2018 Jun; 14(6):797-802. PubMed ID: 29678347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
    Albèr A; Brønden A; Knop FK
    Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fasting levels of glicentin are higher in Roux-en-Y gastric bypass patients exhibiting postprandial hypoglycemia during a meal test.
    Poitou C; Bouaziz-Amar E; Genser L; Oppert JM; Lacorte JM; Le Beyec J
    Surg Obes Relat Dis; 2018 Jul; 14(7):929-935. PubMed ID: 29703503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.
    Craig CM; Liu LF; Deacon CF; Holst JJ; McLaughlin TL
    Diabetologia; 2017 Mar; 60(3):531-540. PubMed ID: 27975209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Huixing L; Di F; Daoquan P
    Clin Ther; 2023 Jan; 45(1):17-30. PubMed ID: 36604209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.
    Kittah E; Camilleri M; Jensen MD; Vella A
    Metab Syndr Relat Disord; 2020 Nov; 18(9):406-412. PubMed ID: 32833560
    [No Abstract]   [Full Text] [Related]  

  • 16. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
    Triplitt C; Solis-Herrera C
    Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies.
    Hindsø M; Svane MS; Hedbäck N; Holst JJ; Madsbad S; Bojsen-Møller KN
    Surg Obes Relat Dis; 2021 Jul; 17(7):1383-1391. PubMed ID: 33771461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.